United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer and BioNTech said they have submitted early-stage clinical trial data to the FDA as part of their application seeking U.S. OK of a Covid booster shot.

Pfizer submits data to FDA for authorization of Covid vaccine booster shot for general population

BioNTech SE

Pfizer Inc. PFE, +0.33% and partner BioNTech SE BNTX, -10.29% announced Monday that data from a Phase 1 study has been submitted to the U.S. Food and Drug Administration, for the evaluation of a third, booster dose of their COVID-19 vaccine. The companies said they will also submit the data to the European Union's version of the FDA, the European Medicines Agency, as well as other regulatory authorities, in the coming weeks.

Pfizer, BioNTech submit trial data on COVID-19 booster shot to FDA

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies' COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “Vaccination is our most effective means of preve

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

The FDA approved Pfizer Inc's (NYSE:PFE) TICOVAC (tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals one year of age and older. TICOVAC was developed using a master 'seed' virus similar to the TBE virus found in nature.

FDA Approves Pfizer's Tick-Borne Encephalitis Vaccine

Merck

Pfizer traded up to its May '99 all-time-high this week after lagging for 21 years. Merck traded up to its December '2000, all-time-high of $87.25 in early 2020, but has traded lower since.

Pfizer And Merck: Two Long-Term Laggards In A Momentum Market, As Pfizer Gets A Catalyst From Covid-19

Johnson & Johnson

Moderna

These strengthening tailwinds will power future returns.

4 Reasons to (Still) Be Optimistic About Coronavirus Vaccine Stocks

The big pharma stock definitely has its positives.

3 Reasons Why You Should Consider Buying Pfizer Stock

American Airlines

Apple

Carnival

Delta Air Lines

Disney

Ford Motor Company

General Electric

Tesla

DailyFX analyzed Robinhood data to identify millennials' favorite stocks during the 12 months to April.

Millennials plowed their money into Apple, Tesla, and Disney during the pandemic. Here are their 10 favorite stocks.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TICOVAC™ (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older.1 TICOVAC™ is the only FDA-approved vaccine to help protect U.S. adults and children against the TBE virus when visiting or living in TBE endemic areas. Following today's FDA approval, the U.S. Centers for Disease Control and Prevention's (CDC)

U.S. FDA Approves TICOVAC™, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine

The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.

Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate

Year-to-date, shares of BioNTech, Moderna, and Pfizer have surged 357%, 275%, and 28%, respectively.

Moderna and Pfizer rebound after FDA authorizes third COVID-19 booster shot for immunocompromised

Pfizer and Moderna could make billions of dollars from COVID-19 booster shots, earnings comparable to the $6 billion generated each year in flu vaccine sales. That's according to a Friday (Aug. 13) report from Reuters, which says the companies expect vaccinated people will need boosters to project against the coronavirus and new variants.

Pfizer, Moderna Could Make Billions From COVID Boosters

The FDA authorized booster doses for immunocompromised individuals.

Why Pfizer, BioNTech, and Moderna Stocks Are Getting a Bump Today

We're seeing the laws of supply and demand at work.

Why Are Pfizer and Moderna Jacking Up COVID Vaccine Prices?

Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.

Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market

Adobe

Danaher

Alphabet

Microsoft

COVID-19 cases have spiked recently due to a highly transmissible strain. Here's a list of delta variant stocks that could get a boost as cases continue to ramp up.

6 Stocks to Buy as Delta Variant Cases Surge

The shares of Pfizer Inc. (NYSE: PFE) increased by over 1.9% during intraday trading. This is why it happened.

Pfizer Shares Increase Over 1.9% Intraday: Why It Happened

Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.

mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally

The pre-print study suggested the Pfizer vaccine was 34 points less effective in preventing infection last month, at least in one state, NBC New York reports.

Mayo Clinic: COVID Breakthrough Risk May Be Much Lower With Moderna Than Pfizer

The study charted the effectiveness of mRNA vaccines given out in the Mayo Clinic Health System in Minnesota between January and July.

Pfizer's vaccine efficacy dropped to 42% while Moderna's was at 76% when the Delta variant became the dominant strain, study says

Pfizer is on a roll right now. But the stock still faces risks.

3 Reasons Why You Might Not Want to Buy Pfizer Stock

The U.S. Food and Drug Administration is expected to authorize on Thursday a third dose of the Pfizer Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) and Moderna Inc. (NASDAQ:MRNA) COVID-19 vaccines for certain people with weakened immune systems, the New York Times reported. What Happened: The decision to expand the emergency use of the two COVID-19 vaccines will cover organ transplant recipients and people whose immune systems are similarly compromised, the report noted, citing people familiar with the plans.

FDA Expected To Authorize Moderna, Pfizer COVID-19-Vaccine Third Doses For Some People Today: NYT

The answer ultimately depends on whether the uncertainty plaguing JAK inhibitors resolves positively.

Can Pfizer Seize Share in This Multibillion-Dollar Market?

Atea Pharmaceuticals

Sorrento Therapeutics Inc

Vaxart

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

News for Pfizer Stock (PFE)